Explain this page
Arphra AIPlain-English read on Bio-Techne Corporation’s valuationIncome statement
| In USD | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|---|---|---|---|
| Revenue & profit | |||||||||
| Revenue | $931.03M | $1.11B | $1.14B | $1.16B | $1.22B | $1.21B | $1.26B | $1.38B | $1.45B |
| Cost of revenue | $298.18M | $349.1M | $366.89M | $389.34M | $429.36M | $396.91M | $422.79M | $470.95M | $491.65M |
| Gross profit | $632.85M | $756.5M | $769.82M | $769.73M | $790.27M | $802.88M | $832.63M | $922.93M | $967.6M |
| Gross margin | +67.97% | +68.42% | +67.72% | +66.41% | +64.80% | +66.51% | +65.96% | +66.88% | +66.75% |
| Operating | |||||||||
| Research & development | $70.6M | $87.14M | $92.49M | $96.66M | $99.5M | $98.4M | $104.2M | $113.67M | $121.07M |
| Selling, general & administrative | $289.92M | $339M | $352.44M | $393.32M | $415.1M | $408.28M | $415.63M | $460.33M | $468.54M |
| Total operating expenses | $395.55M | $459.91M | $470.87M | $563.04M | $688.02M | $604.85M | $628.39M | $656.2M | $716.94M |
| Operating income | $237.3M | $296.59M | $298.94M | $206.69M | $102.26M | $207.91M | $227.59M | $238.25M | $250.05M |
| Operating margin | +25.49% | +26.83% | +26.30% | +17.83% | +8.38% | +17.22% | +18.03% | +17.26% | +17.25% |
| EBITDA | $249.87M | $413.76M | $457.11M | $313.14M | $216.88M | $345.68M | $367.05M | $398.45M | $406.18M |
| EBIT | $162.13M | $312.7M | $349.87M | $201.43M | $106.97M | $222.37M | $241.77M | $254.26M | $278.59M |
| Below the line | |||||||||
| Interest expense | $13.95M | $11.31M | $11.22M | $15.74M | $8.51M | $12.29M | $12.59M | $13.87M | $14.62M |
| Interest income | $473K | $794K | $3.41M | $3.32M | $3.89M | $3.7M | $3.8M | $4.05M | $4.48M |
| Other income / expense | -$89.12M | $4.8M | $39.72M | -$21M | -$3.79M | — | — | — | — |
| Pre-tax income | $148.18M | $301.39M | $338.66M | $185.69M | $98.46M | $213.61M | $222.47M | $241.43M | $262.6M |
| Income tax expense | $8.59M | $38.29M | $53.22M | $17.58M | $25.06M | $35.91M | $38.53M | $42.32M | $45.19M |
| Earnings | |||||||||
| Net income | $140.41M | $272.05M | $285.26M | $168.11M | $73.4M | $183.08M | $197.11M | $204.91M | $223.13M |
| Net income · continuing ops | $139.59M | $263.1M | $285.44M | $168.11M | $73.4M | $188.04M | $191.83M | $205.29M | $222.15M |
| Net margin | +15.08% | +24.61% | +25.10% | +14.50% | +6.02% | +15.17% | +15.61% | +14.85% | +15.39% |
| EPS · basic | $0.91 | $1.73 | $1.81 | $1.07 | $0.47 | $1.96 | $2.09 | $2.41 | $2.66 |
| EPS · diluted | $0.87 | $1.66 | $1.76 | $1.05 | $0.46 | $1.93 | $2.07 | $2.33 | $2.60 |
| EPS · low estimate | — | — | — | — | — | $1.85 | $1.91 | $2.18 | $2.56 |
| EPS · high estimate | — | — | — | — | — | $1.97 | $2.21 | $2.50 | $2.66 |
| Shares · basic | 154.99M | 156.88M | 157.18M | 157.71M | 157.52M | 156.72M | 158.69M | 157.85M | 157.16M |
| Shares · diluted | 161.93M | 164.12M | 161.86M | 160.77M | 159.72M | 161.03M | 159.12M | 158.63M | 160.32M |
| Coverage | |||||||||
| Analysts (revenue) | — | — | — | — | — | 11 | 9 | 8 | 6 |
| Analysts (EPS) | — | — | — | — | — | 8 | 8 | 3 | 1 |
Coverage notes. Historical figures come’s as-reported income statements / balance sheets / cash flows in our data warehouse. Forecast columns (italicised, faint accent tint) carry vendor-supplied numbers where available (revenue + EPS consensus) and ratio-derived values for every other line. Margins / ratios are the trailing-3y average from history applied to the forecast revenue; values are clamped to enforce P&L identity (gross ≥ operating, EBITDA ≥ operating, net ≤ operating) and balance-sheet identity (assets = liabilities + equity by construction). Cash-flow FCF reconciles to OCF + CapEx. USD conversion uses the period-end close of the issuer's reported/USD pair from forex_prices_daily; share counts stay unconverted.
Financials
Full income statement, balance sheet, and cash-flow history is included with Pro.
Upgrade to Pro